Actuate Therapeutics (ACTU) announced that elraglusib in combination with gemcitabine/nab-paclitaxel met the primary endpoints and achieved statistical significance in topline results from its ongoing Phase 2 trial in first-line treatment of metastatic pancreatic ductal adenocarcinoma. The topline results, which demonstrate a substantial improvement in median overall survival benefit in the elraglusib/GnP combination arm compared to the results announced in December 2024, will be presented on May 31, 2025, at the Annual Meeting of the American Society of Clinical Oncology, ASCO. Topline data shows statistically significant improvement in overall survival in elraglusib plus GnP combination arm versus GnP control arm; Elraglusib/GnP combination arm demonstrated substantial improvement in median overall survival since the last data analysis; Clinical trial meets primary endpoint for overall survival and confirms significant 1-year survival rate; Elraglusib/GnP combination arm demonstrated a favorable risk-benefit profile; Topline dataset to be presented in an oral presentation at the upcoming ASCO Annual Meeting ; Company plans to work with regulators to expeditiously bring elraglusib to commercialization
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACTU:
- Craig-Hallum bullish on Actuate Therapeutics, initiates with a Buy
- Actuate Therapeutics initiated with a Buy at Craig-Hallum
- Actuate Therapeutics files to sell 3.9M shares of common stock for holders
- Actuate Therapeutics: Promising Phase 2 Results and Market Potential for Elraglusib in Metastatic Pancreatic Cancer
- Actuate Therapeutics initiated with a Buy at H.C. Wainwright